發(fā)布時間：2018-04-30 20:31

  本文選題：肝腫瘤 + 肝硬化　； 參考：《中國全科醫(yī)學(xué)》2017年20期

【摘要】：目的應(yīng)用基質(zhì)輔助激光解吸電離飛行時間質(zhì)譜(MALDI-TOF-MS)技術(shù)分析乙型肝炎肝硬化至肝癌過程中血清標(biāo)志蛋白的變化,以期發(fā)現(xiàn)早期肝癌甚至癌前病變時的血清標(biāo)志物。方法選取2010—2012年首都醫(yī)科大學(xué)附屬北京世紀(jì)壇醫(yī)院收治的乙型肝炎肝硬化患者240例,對其進(jìn)行隨訪,為期3年,每6個月抽血1次,保存血清。其中12例患者在隨訪過程中確診為原發(fā)性肝癌,2例患者留取血樣量不足,僅對10例患者的血樣進(jìn)行分析。對完成隨訪未進(jìn)展為肝癌的209例乙型肝炎肝硬化患者按照性別、年齡匹配選取40例。并選取同期本院體檢中心健康者的血樣40例。應(yīng)用MALDI-TOF-MS技術(shù)分析患者血清蛋白質(zhì)組學(xué)的變化。結(jié)果應(yīng)用CM10芯片共檢測出109個蛋白峰,其中具有差異的蛋白質(zhì)分子量分別為:4 350.8 Da、6 858.5 Da、7 571 Da、15 125 Da、15 893 Da。其中4 350.8 Da隨著肝癌的發(fā)生逐漸呈上調(diào)趨勢,6 858.5 Da、7 571 Da、15 125 Da、15 893 Da隨著肝癌的發(fā)生呈下調(diào)趨勢。結(jié)論隨著肝癌的發(fā)生,分子量為4 350.8 Da的蛋白質(zhì)呈逐漸上調(diào)趨勢,其余6 858.5 Da、7 571 Da、15 125 Da、15 893 Da蛋白質(zhì)呈逐漸下調(diào)趨勢。
[Abstract]:Objective to analyze the changes of serum marker proteins in the process of hepatitis B cirrhosis and liver cancer by matrix assisted laser desorption and ionization time of flight mass spectrometry (MALDI-TOF-MSM), in order to find the serum markers of early liver cancer and even precancerous lesions. Methods 240 patients with hepatitis B cirrhosis treated in Beijing Century altar Hospital affiliated to Capital Medical University from 2010 to 2012 were followed up for 3 years. Among them, 12 cases were diagnosed as primary liver cancer during follow-up, 2 cases had insufficient blood sample, only 10 cases were analyzed. Forty patients with hepatitis B cirrhosis were selected according to their sex and age. Blood samples were collected from 40 healthy subjects in the same period. The changes of serum proteomics were analyzed by MALDI-TOF-MS technique. Results A total of 109 protein peaks were detected by using CM10 microarray. The molecular weights of the proteins with different molecular weights were respectively 1: 4 350.8 DaC6 858.5 Da571 Da571 Da15125 Da1 15893 Da. Among them, 4 350.8 Da increased gradually with the occurrence of HCC. 6 858.5 Da571 Da125125 Da593 Da showed a downward trend with the occurrence of HCC. Conclusion with the development of HCC, the protein with molecular weight of 4 350.8 Da was gradually up-regulated, while the other 6 858.5 Da571 Da571 Da125125 Da1 15893 Da protein was gradually down-regulated.
【作者單位】： 首都醫(yī)科大學(xué)附屬北京世紀(jì)壇醫(yī)院消化內(nèi)科;
【分類號】：R512.62;R575.2;R735.7

【相似文獻(xiàn)】

相關(guān)期刊論文 前10條

1 李梵;陳國鳳;邵清;紀(jì)冬;李永綱;韓萍;閆濤;陳菊梅;;乙型肝炎肝硬化患者108例預(yù)后分析[J];肝臟;2007年06期

2 張敬華;;79例乙型肝炎肝硬化后反復(fù)發(fā)作的影響因素分析[J];中國傷殘醫(yī)學(xué);2013年04期

3 鄒同;;乙型肝炎肝硬化反復(fù)發(fā)作的影響因素分析[J];中醫(yī)臨床研究;2013年15期

4 馬慧;郭芳;魏來;朱賽楠;孫焱;王豪;;HBeAg陰性乙型肝炎肝硬化患者死亡的影響因素分析[J];中國實用內(nèi)科雜志;2006年S2期

5 閻雙緩;曹治宸;馬英;孔麗;;乙型肝炎肝硬化合并單純血小板減少1例[J];臨床薈萃;2007年06期

6 石偉珍;過建春;施軍平;王宇芳;荀運(yùn)浩;;抗乙肝胎盤轉(zhuǎn)移因子治療乙型肝炎肝硬化療效觀察[J];醫(yī)學(xué)研究雜志;2008年03期

7 陶明玲;張世斌;陳新月;;男性乙型肝炎肝硬化患者血清瘦素及血脂水平的研究[J];實用肝臟病雜志;2008年03期

8 徐維國;楊麗;劉小菁;強(qiáng)鷗;;CC族趨化因子受體基因多態(tài)性在乙型肝炎肝硬化中的作用[J];臨床薈萃;2009年03期

9 薛建波;林懋惺;楊麗;;血管緊張素轉(zhuǎn)換酶及血管緊張素Ⅱ1型受體基因多態(tài)性與乙型肝炎肝硬化的關(guān)系[J];臨床薈萃;2009年08期

10 宮Z，

本文編號：1826108